---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-007717"
form_type: "8-K"
ticker: "COGT"
cik: "0001622229"
company_name: "Cogent Biosciences, Inc."
filed_at: "2023-03-14T23:59:59+00:00"
generated_at: "2026-06-18T03:20:57.089725+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cogent Biosciences reports FY2022 net loss $140.2M, cash $259.3M; outlines bezuclastinib milestones for 2023

## Summary
- Net loss $39.6M Q4, $140.2M FY2022 vs $72.3M FY2021; R&D expenses $121.6M FY2022.
- Cash, equivalents and marketable securities $259.3M as of Dec 31, 2022; runway into 2025.
- APEX Part 2 initiation planned mid-2023; updated Phase 3 PEAK lead-in data expected 1H23.
- Initial SUMMIT Phase 2 data in nonadvanced systemic mastocytosis expected 2H23.
- Appointed Rachael Easton, M.D., Ph.D., VP Head of Clinical Development; Sylvia Adams to SAB.

## SEC filing metadata
- accession: 0000950170-23-007717
- form_type: 8-K
- ticker: COGT
- cik: 0001622229
- company_name: Cogent Biosciences, Inc.
- filed_at: 2023-03-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1622229/000095017023007717/0000950170-23-007717-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1622229/000095017023007717/cogt-20230314.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-007717
- JSON: https://secwatch.observer/filing/0000950170-23-007717.json
- Plain text: https://secwatch.observer/filing/0000950170-23-007717.txt

## Key facts
- Earnings Releases
  Cogent Biosciences, Inc. reported financial results for the fourth quarter and full year of 2022.
  - Period: the fourth quarter and full year of 2022
  - Result: reported results
  source text: On March 14, 2023, Cogent Biosciences, Inc., a Delaware corporation (the “Company”), issued a press release announcing its financial results for the quarter and year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1622229/000095017023007717/0000950170-23-007717-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.